Want to see JP:4896 full AI Analyst Report?

K Pharma,Inc. (4896) Price & Analysis

0 Followers

4896 Stock Chart & Stats

¥651.00

¥14.00(2.16%)

At close: Jan 08 4:00 PM EST

¥651.00

¥14.00(2.16%)

Day’s Range― - ―

52-Week Range¥604.00 - ¥949.00

Previous CloseN/A

Volume10.50K

Average Volume (3M)48.08K

Market Cap

¥8.84B

Enterprise Value¥7.25K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.72

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-20.84

Shares Outstanding11,622,600

10 Day Avg. Volume47,520

30 Day Avg. Volume48,080

Financial Highlights & Ratios

PEG Ratio-0.44

Price to Book (P/B)6.05

Price to Sales (P/S)0.00

P/FCF Ratio-8.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Prior Commercial Profitability (2023)The company posted ¥1.0B revenue and ¥260M net income in 2023, demonstrating prior ability to generate commercial revenue and profit. That historical execution implies the organization has operational capabilities and commercial pathways that could be redeployed if revenue is restored.

Reduced Cash Burn In 2025Operating and free cash flow showed modest improvement in 2025 versus 2024, indicating partial success in cost control or operational tightening. Sustained reduction in burn lengthens runway, lowers near-term refinancing pressure, and raises the probability management reaches key milestones before needing large external funding.

Tangible Asset Base Provides BufferThe company retains roughly ¥2.94B in total assets and positive equity, providing a tangible balance-sheet cushion. That asset base can underwrite ongoing R&D, serve as collateral for financing, or be leveraged in partnerships, preserving strategic optionality while operations are stabilised.

Bears Say

Zero Recent Revenue And Large LossesThe company reported zero revenue in 2024–2025 after prior revenue in 2023, resulting in large operating and net losses. Loss of revenue eliminates margin support and recurring cash inflows, forcing dependency on external funding and making long-term viability contingent on returning to revenue generation.

Sustained Negative Cash GenerationPersistent negative operating and free cash flow of roughly -¥0.98B to -¥0.92B annually reflects ongoing cash burn tied to operations. Continued cash outflows will deplete reserves, increase the need for dilution or debt, and constrain the company’s ability to fund development programs without material external capital.

Eroding Equity And Rising LeverageEquity has meaningfully declined while debt rose to ¥1.5B, lifting debt-to-equity to about 1.19x. The shrinking capital base and higher leverage reduce financial flexibility, heighten refinancing and solvency risk during setbacks, and increase the cost of capital for future funding needs.

4896 FAQ

What was K Pharma,Inc.’s price range in the past 12 months?

K Pharma,Inc. lowest stock price was ¥604.00 and its highest was ¥949.00 in the past 12 months.

What is K Pharma,Inc.’s market cap?

K Pharma,Inc.’s market cap is ¥8.84B.

When is K Pharma,Inc.’s upcoming earnings report date?

K Pharma,Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 79 days.

How were K Pharma,Inc.’s earnings last quarter?

K Pharma,Inc. released its earnings results on Aug 13, 2026. The company reported -¥20.84 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is K Pharma,Inc. overvalued?

According to Wall Street analysts K Pharma,Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does K Pharma,Inc. pay dividends?

K Pharma,Inc. does not currently pay dividends.

What is K Pharma,Inc.’s EPS estimate?

K Pharma,Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does K Pharma,Inc. have?

K Pharma,Inc. has 11,622,600 shares outstanding.

What happened to K Pharma,Inc.’s price movement after its last earnings report?

K Pharma,Inc. reported an EPS of -¥20.84 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.937%.

Which hedge fund is a major shareholder of K Pharma,Inc.?

Currently, no hedge funds are holding shares in JP:4896

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

K Pharma,Inc.

K Pharma, Inc., headquartered in Minato, Japan, was established in 2016 and operates within the Japanese market. The company is dedicated to the research, development, production, and sale of both regenerative medicines and pharmaceutical products. A key focus within their regenerative medicine efforts involves leveraging disease-specific induced pluripotent stem (iPS) cell technology, primarily to develop treatments for conditions such as spinal cord injuries and cerebral infarctions.